"We are thrilled to have our EU distribution hub now operational with deliveries beginning in the coming days," said Seedo CEO Zohar Levy. "We plan to continue to optimize our supply-chain protocols, improving after-sale customer service, while developing new sales market opportunities."
As part of Seedo's recent momentum, the company announced a partnership with Kibbutz Dan in Northern Israel to establish the first fully automated, commercial-scale, pesticide-free containerized cannabis farm in Israel. The company also recently signed an agreement to establish a medical cannabis farm in Moshav Brosh, Israel. Additionally, SodaStream CEO Daniel Birnbaum, who recently joined the company's board of directors, spearheaded a private placement round of over $4 million in capital. The company also recently appointed Dr. Jendayi Frazer, the former U.S. Assistant Secretary of State for African Affairs and one of the nation's leading voices for international policy, to its board of directors.
About Seedo
Seedo is a market leading high-tech company providing the hemp and agriculture industries with the world's first fully automated and controlled indoor growing machine. Seedo provides growers with the freedom to cut costs while generating high yields of lab-grade, pesticide-free herbs and vegetables. Seedo's AI-powered, turnkey systems enable anyone from average consumers to large-scale producers the ability to grow without prior experience or ample space. Seedo is a publicly traded company backed by a group of international investors including Cannabics Pharmaceuticals and is headquartered in Israel. For more information, visit http://www.seedolab.com
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest Form 10-K Report filed on January 15th, 2019. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
Contacts:
Seedo Corp.
+972-546-642-228
General Information: [email protected]
http://www.seedolab.com
SOURCE Seedo Corp.
Related Links
http://www.seedolab.com./
Share this article